Centogene N.V. Stock News

Centogene N.V. (CNTG) CEO Kim Stratton on Q4 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,

Hoboken, NJ, Rostock/Berlin, Germany, Feb 22, 2022 - (ACN Newswire) - Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion. As part of the current investment-series the Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) are investing a single-digit million to further expand into the US and GCC regions. For MBMV, it is a very special investment, as Managing Director Dr. Thomas Drews reveals: "With Arcensus, we are investing in a very experienced and well-known team and in a technology which, in precisely this combination, has the potential to make a major contribution to the prevention of diseases and the cure of rare diseases". He continues: "In addition, we are proud that a local company from Rostock is able to play as a figurehead at the top of the international biotech scene." Indeed, the team around Prof.

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc. (NASDAQ: AXSM ) disclosed in a filing that it reached a settlement with Baudax Bio, Inc. (NASDAQ: BXRX ) with regard to a lawsuit alleging that Axsome''s AXS-07 infringed a couple of patents owned by Baudax. Under the settlement agreement, Baudax is to voluntarily dismiss the lawsuit and Axsome will make a one-time payment of $312,500 to Baudax. Axsome has not incurred any obligation to pay any royalty or other contingent consideration nor has it agreed to any other restriction on its manufacture or distribution of AXS-07. Axsome shares were down 3.01% to $29.60 in premarket trading. Editas Announces Termination Of Chief Medical Office With Immediate Effect Editas Medicine, Inc. (NASDAQ: EDIT ) said in a filing with the SEC that Lisa Michaels'' employment with Editas as its chief medical officer was terminated, effective immediately.

Centogene (CNTG) plans for the transition of CFO René Just and the appointment of Miguel Coego Rios as EVP, Finance & Legal and Interim CFO.René Just has resigned effective Mar.31,…

Centogene (CNTG) and Insilico Medicine are collaborating to discover novel therapeutic targets for Niemann-Pick disease type C ((NPC)) using artificial intelligence.NPC is a

Leveraging AI to Accelerate the Path From Diagnosis to Cure Leveraging AI to Accelerate the Path From Diagnosis to Cure

Marshall Wace LLP bought a new position in shares of Centogene (NASDAQ:CNTG) during the 2nd quarter, Holdings Channel.com reports. The firm bought 18,691 shares of the companys stock, valued at approximately $195,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CNTG. Millennium Management LLC []

Zacks Investment Research lowered shares of Centogene (NASDAQ:CNTG) from a hold rating to a strong sell rating in a report published on Tuesday morning, Zacks.com reports. According to Zacks, Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The []

Robert W. Baird reissued their buy rating on shares of Centogene (NASDAQ:CNTG) in a research note published on Sunday morning, Price Targets.com reports. The firm currently has a $14.00 target price on the stock. Separately, Zacks Investment Research upgraded Centogene from a strong sell rating to a hold rating in a research note on Tuesday, []

Centogene NV (CNTG) shares closed this week 21.4% lower than it did at the end of last week. The stock is currently down 33.2% year-to-date, down 38.4% over the past 12 months, and down 42.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $9.52 and as low as $6.76 this week.Trading volume this week was 338.0% higher than the 10-day average and 710.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Industrials industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8.6% The company's stock price performance over the past 12 months lags the peer average by 58.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Centogene (NASDAQ:CNTG) announced its earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.47), Fidelity Earnings reports. Centogene had a negative net margin of 6.88% and a negative return on equity of 25.39%. During the same period in the prior year, the []

Centogene (NASDAQ:CNTG) released its quarterly earnings data on Wednesday. The company reported ($1.08) EPS for the quarter, missing analysts consensus estimates of ($0.59) by ($0.49), Yahoo Finance reports. Centogene had a negative return on equity of 25.39% and a negative net margin of 6.88%. During the same period in the previous year, the company earned []

Centogene N.V. (NASDAQ: CNTG) Q3 2021 earnings call dated Nov. 24, 2021 Presentation: Operator Ladies and gentlemen, thank you for standing by and welcome to Centogene Q3 2021 Earning Results. [] The post Centogene N.V. (CNTG) Q3 2021 Earnings Call Transcript first appeared on AlphaStreet .